Robust Bayesian decision theory applied to optimal dosage

被引:4
作者
Abraham, C
Daurès, JP
机构
[1] ENSAM, UMR Anal Syst & Biometrie, F-34060 Montpellier 1, France
[2] Univ Montpellier, Inst Rech Clin Montreal, Lab Biostat, F-34059 Montpellier, France
关键词
class of loss functions; optimal medical treatment; robust Bayesian decision theory; utility function;
D O I
10.1002/sim.1690
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We give a model for constructing an utility function u(theta,d) in a dose prescription problem. 0 and d denote respectively the patient state of health and the dose. The construction of u is based on the conditional probabilities of several variables. These probabilities are described by logistic models. Obviously, u is only an approximation of the true utility function and that is why we investigate the sensitivity of the final decision with respect to the utility function. We construct a class of utility functions from u and approximate the set of all Bayes actions associated to that class. Then, we measure the sensitivity as the greatest difference between the expected utilities of two Bayes actions. Finally, we apply these results to weighing up a chemotherapy treatment of lung cancer. This application emphasizes the importance of measuring robustness through the utility of decisions rather than the decisions themselves. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:1055 / 1073
页数:19
相关论文
共 20 条
[1]   Global robustness with respect to the loss function and the prior [J].
Abraham, C ;
Daures, JP .
THEORY AND DECISION, 2000, 48 (04) :359-381
[2]   Analytic approximation of the interval of Bayes actions derived from a class of loss functions [J].
Abraham, C ;
Daurès, JP .
TEST, 1999, 8 (01) :129-145
[3]   Asymptotic limit of the Bayes actions set derived from a class of loss functions [J].
Abraham, C .
JOURNAL OF MULTIVARIATE ANALYSIS, 2001, 79 (02) :251-274
[4]  
[Anonymous], 1994, Test
[5]  
Babb J, 1998, STAT MED, V17, P1103, DOI 10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO
[6]  
2-9
[7]   ROBUST BAYESIAN-ANALYSIS - SENSITIVITY TO THE PRIOR [J].
BERGER, JO .
JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1990, 25 (03) :303-328
[8]  
Berger JO, 1984, Robustness of Bayesian Analysis
[9]   Incorporating toxicity considerations into the design of two-stage Phase II clinical trials [J].
Bryant, J ;
Day, R .
BIOMETRICS, 1995, 51 (04) :1372-1383
[10]   Designs for phase II trials allowing for a trade-off between response and toxicity [J].
Conaway, MR ;
Petroni, GR .
BIOMETRICS, 1996, 52 (04) :1375-1386